Chemed (NYSE:CHE - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 22.000-22.300 for the period, compared to the consensus estimate of 23.330. The company issued revenue guidance of -.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on CHE shares. Royal Bank Of Canada reissued an "outperform" rating and set a $640.00 price target (down previously from $674.00) on shares of Chemed in a research note on Monday, June 30th. Bank of America lowered their price target on Chemed from $708.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 30th. Wall Street Zen cut shares of Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Jefferies Financial Group initiated coverage on shares of Chemed in a research report on Friday. They set a "hold" rating and a $500.00 price target on the stock.
Read Our Latest Analysis on Chemed
Chemed Price Performance
CHE stock traded up $1.03 during trading hours on Tuesday, reaching $467.11. The stock had a trading volume of 128,240 shares, compared to its average volume of 130,837. The stock has a market capitalization of $6.83 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.26 and a beta of 0.50. The stock has a 50-day simple moving average of $520.21 and a 200 day simple moving average of $555.91. Chemed has a fifty-two week low of $449.01 and a fifty-two week high of $623.60.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $3.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($2.27). Chemed had a net margin of 12.40% and a return on equity of 27.58%. On average, sell-side analysts forecast that Chemed will post 21.43 EPS for the current fiscal year.
Chemed Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend was Thursday, May 29th. Chemed's dividend payout ratio (DPR) is presently 9.74%.
Insider Transactions at Chemed
In other Chemed news, CEO Kevin J. Mcnamara sold 1,500 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $576.45, for a total transaction of $864,675.00. Following the completion of the transaction, the chief executive officer owned 101,197 shares of the company's stock, valued at approximately $58,335,010.65. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Spencer S. Lee sold 1,500 shares of Chemed stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $577.99, for a total value of $866,985.00. Following the completion of the transaction, the executive vice president directly owned 14,627 shares of the company's stock, valued at approximately $8,454,259.73. This represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,500 shares of company stock worth $2,598,450. Insiders own 3.29% of the company's stock.
Institutional Trading of Chemed
A hedge fund recently raised its stake in Chemed stock. Geneos Wealth Management Inc. boosted its stake in shares of Chemed Corporation (NYSE:CHE - Free Report) by 330.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 99 shares of the company's stock after acquiring an additional 76 shares during the quarter. Geneos Wealth Management Inc.'s holdings in Chemed were worth $61,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 95.85% of the company's stock.
About Chemed
(
Get Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
